Advertisement

Applied Biochemistry and Biotechnology

, Volume 186, Issue 4, pp 1034–1046 | Cite as

An Enzyme Immunoassay for Determining Immunoreactive Trypsinogen (IRT) in Dried Blood Spots on Filter Paper Using an Ultra-Microanalytical System

  • Elisa M. Castells MartínezEmail author
  • Ernesto Carlos González
  • Yileidis Tejeda
  • Amarilys Frómeta
  • Odalys Martín
  • Maryeris Espinosa
  • Lesley del Río
  • Pedro L. Pérez
  • Greilys Morejón
  • Yenitse Perea
  • Antonio Melchor
Article

Abstract

Cystic fibrosis (CF) is a severe autosomal recessive disorder. It is caused by mutations in the CF transmembrane conductance regulator gene. Early diagnosis of CF can be carried out by determining high immunoreactive trypsinogen (IRT) blood values in newborns. A simple sandwich-type ultramicroELISA assay (UMELISA®) has been developed for the measurement of IRT in dried blood spots on filter paper. Strips coated with a high affinity monoclonal antibody directed against IRT are used as solid phase, to ensure the specificity of the assay. The assay is carried out within 20 h. The useful rank of the curve is 0–500 ng/mL, and the lowest detectable concentration is 4.8 ng/mL. Intra- and inter-assay coefficients of variation were lower than 10%. The recovery mean value was 100.3 ± 11.2%. Cross-reactivity with proteins structurally related to IRT (α2-macroglobulin, α1-antitrypsin, and human chymotrypsin) was lower than the detection limit of the assay. Four thousand four hundred six newborn samples from the Cuban Newborn Screening Program were analyzed, and the mean IRT concentration was 12.8 ng/mL. Higher IRT values were obtained when samples were eluted overnight. Regression analysis showed a good correlation with the commercially available AutoDELFIA® Neonatal IRT kit (n = 3948, r = 0.885, ƙ = 0.976, p < 0.01). The analytical performance characteristics of our UMELISA® TIR Neonatal suggest that it can be used for the neonatal screening of CF.

Keywords

Cystic fibrosis IRT Newborn screening UMELISA® Blood spots 

Abbreviations

CF

cystic fibrosis

NBS

newborn screening

IRT

immunoreactive trypsinogen

ELISA

enzyme-linked immunosorbent assay

SUMA

Ultra Micro Analytical System

UMELISA

ultramicro enzyme-linked immunosorbent assay

Notes

Acknowledgements

We thank Lic. José Luis Fernández Sierra for his valuable help in the final language revision of the manuscript.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Parad, R. B., & Comeau, A. M. (2003). Newborn screening for cystic fibrosis. Pediatric Annals, 32(8), 528–535.CrossRefGoogle Scholar
  2. 2.
    Sontag, M. K., Hammond, K. B., Zielenski, J., Wagener, J. S., & Accurso, F. J. (2005). Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes. The Journal of Pediatrics, 147(3), S83–S88.CrossRefGoogle Scholar
  3. 3.
    Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., Lok, S., Plavsic, N., & Chou, J. L. (1989). Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science (New York, NY), 245, 1066–1073.CrossRefGoogle Scholar
  4. 4.
    Massie, R. J., Curnow, L., Glazner, J., Armstrong, D. S., & Francis, I. (2012). Lessons learned from 20 years of newborn screening for cystic fibrosis. The Medical Journal of Australia, 196(1), 67–70.CrossRefGoogle Scholar
  5. 5.
    Robinson, P. (2001). Cystic fibrosis. Thorax, 56(3), 237–241.CrossRefGoogle Scholar
  6. 6.
    Dijk, F. N., & Fitzgerald, D. A. (2012). The impact of newborn screening and earlier intervention on the clinical course of cystic fibrosis. Paediatric Respiratory Reviews, 13(4), 220–225.CrossRefGoogle Scholar
  7. 7.
    Farrell, P. M., Kosorok, M. R., Laxova, A., Shen, G., Koscik, R. E., Bruns, W. T., Splaingard, M., & Mischler, E. H. (1997). Nutritional benefits of neonatal screening for cystic fibrosis Wisconsin cystic fibrosis neonatal screening study group. The New England Journal of Medicine, 337(14), 963–969.CrossRefGoogle Scholar
  8. 8.
    Grosse, S. D., Rosenfeld, M., Devine, O. J., Lai, H. J., & Farrell, P. M. (2006). Potential impact of newborn screening for cystic fibrosis on child survival: a systematic review and analysis. The Journal of Pediatrics, 149(3), 362–366.CrossRefGoogle Scholar
  9. 9.
    VanDevanter, D. R., Pasta, D. J., & Konstan, M. W. (2014). Improvements in lung function and height among cohorts of 6-year-olds with cystic fibrosis from 1994 to 2012. The Journal of Pediatrics, 165(6), 1091–1097.CrossRefGoogle Scholar
  10. 10.
    Crossley, J. R., Elliott, R. B., & Smith, P. A. (1979). Dried-blood spot screening for cystic fibrosis in the newborn. Lancet, 1(8114), 472–474.CrossRefGoogle Scholar
  11. 11.
    Castellani, C., Southern, K. W., Brownlee, K., Dankert Roelse, J., Duff, A., Farrell, M., Mehta, A., Munck, A., Pollitt, R., Sermet-Gaudelus, I., Wilcken, B., Ballmann, M., Corbetta, C., de Monestrol, I., Farrell, P., Feilcke, M., Férec, C., Gartner, S., Gaskin, K., Hammermann, J., Kashirskaya, N., Loeber, G., Macek Jr., M., Mehta, G., Reiman, A., Rizzotti, P., Sammon, A., Sands, D., Smyth, A., Sommerburg, O., Torresani, T., Travert, G., Vernooij, A., & Elborn, S. (2009). European best practice guidelines for cystic fibrosis neonatal screening. Journal of Cystic Fibrosis, 8(3), 153–173.CrossRefGoogle Scholar
  12. 12.
    Smyth, A. R., Bell, S. C., Bojcin, S., Bryon, M., Duff, A., Flume, P., Kashirskaya, N., Munck, A., Ratjen, F., Schwarzenberg, S. J., Sermet-Gaudelus, I., Southern, K. W., Taccetti, G., Ullrich, G., & Wolfe, S. (2014). European cystic fibrosis society standards of care: best practice guideline. Journal of Cystic Fibrosis, 13(Suppl. 1), S23–S42.CrossRefGoogle Scholar
  13. 13.
    Gonska, T., & Ratjen, F. (2015). Newborn screening for cystic fibrosis. Expert Review of Respiratory Medicine, 9(5), 619–631.CrossRefGoogle Scholar
  14. 14.
    Wilson, J.M.G., &Jungner, G. (1968). Principles and practice of screening for disease. Public Health Papers No. 34. Geneva: World Health Organization.Google Scholar
  15. 15.
    De Boeck, K., Wilschanski, M., Castellani, C., Taylor, C., Cuppens, H., Dodge, J., & Sinaasappel, M. (2006). Cystic fibrosis: terminology and diagnostic algorithms. Thorax, 61(7), 627–635.CrossRefGoogle Scholar
  16. 16.
    González, E. C., Castells, E. M., Frómeta, A., Arteaga, A. L., Del Río, L., Tejeda, Y., Pérez, P. L., Segura, M. T., Almenares, P., Perea, Y., Carlos, N. M., Robaina, R., & Fernández-Yero, J. L. (2016). SUMA technology and newborn screening tests for inherited metabolic diseases in Cuba: an overview of the first 30 years. Journal of Inborn Errors of Metabolism & Screening, 4, 1–9.Google Scholar
  17. 17.
    Morejón, G., Feal, S., Lafita, Y., Castells, E., Quintana, J.M., Hernández, L., García, I., Pupo, M., González, E.C., &Stable, I. (2017). Obtención y caracterización de anticuerpos monoclonales antitripsina humana para el diagnóstico de la fibrosis quística. Poster presented at: X Jornada Latinoamericana de Hematología, Inmunologíay Medicina Transfucional. V Taller Internacional de Hemofilia y Trastornos de la Coagulación. III Taller de Inmunodeficiencias Primarias. VIII Congreso Cubano de Hematología; May8–12,Havana, Cuba.Google Scholar
  18. 18.
    Marrero, N., Zulueta, O., González, E. C., Montalvo, G., Pérez, P. L., & Melchor, A. (2003). Obtention of 17α-hydroxyprogesterone/alkaline phosphatase conjugates for use in the diagnosis of congenital adrenal hyperplasia. Revista CENIC / Ciencias Biológicas, 34(1), 23–28.Google Scholar
  19. 19.
    CLSI Protocols for determination of limits of detection and limits of quantitation. (2004). Approved guideline. CLSI document EP17-A. Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite1400, Wayne, Pennsylvania 19087–1898 USA.Google Scholar
  20. 20.
    CLSI Protocols for evaluation of precision performance of quantitative measurement methods (2004). Approved guideline. CLSI document EP05-A2. Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite1400, Wayne, Pennsylvania 19087–1898 USA.Google Scholar
  21. 21.
    Wild, D. (1994). The immunoassay handbook. MacMillan, p.83–100.Google Scholar
  22. 22.
    Landis, J. R., & Koch, G. G. (1977). The measurement of observer agreement for categorical data. Biometrics, 33(1), 159–174.CrossRefGoogle Scholar
  23. 23.
    Petros, M. (2012). Revisiting the Wilson-Jungner criteria: how can supplemental criteria guide public health in the era of genetic screening? Genetics in Medicine, 14(1), 129–134.CrossRefGoogle Scholar
  24. 24.
    Farrell, P. M., Kosorok, M. R., Rock, M. J., Laxova, A., Zeng, L., Lai, H. C., Hoffman, G., Laessig, R. H., & Splaingard, M. L. (2001). Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves longterm growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group Pediatrics, 107, 1–13.Google Scholar
  25. 25.
    Wilcken, B., & Wiley, V. (2003). Newborn screening methods for cystic fibrosis. Paediatric Respiratory Reviews, 4(4), 272–277.CrossRefGoogle Scholar
  26. 26.
    Southern, K. W., Munck, A., Pollitt, R., Travert, G., Zanolla, L., Dankert-Roelse, J., & Castellani, C. (2007). A survey of newborn screening for cystic fibrosis in Europe. Journal of Cystic Fibrosis, 6(1), 57–65.CrossRefGoogle Scholar
  27. 27.
    Castellani, C., Massie, J., Sontag, M., & Southern, K. W. (2016). Newborn screening for cystic fibrosis. The Lancet Respiratory Medicine, 4(8), 653–661.CrossRefGoogle Scholar
  28. 28.
    Silva Filho, L. V. R. F., Castaños, C., & Hernán, H. (2016). Cystic fibrosis in Latin America—improving the awareness. Journal of Cystic Fibrosis, 15(6), 791–793.CrossRefGoogle Scholar
  29. 29.
    Reed, G. (2009). Generating appropriate technologies for health equity: José Luis Fernández Yero (interview). MEDICC Review, 11(1), 14–17.PubMedGoogle Scholar
  30. 30.
    Therrell Jr., B., Hannon, H., Hoffman, G., Ojodu, J., & Farrell, P. M. (2012). Immunoreactive trypsinogen (IRT) as a biomarker for cystic fibrosis: challenges in newborn dried blood spot screening. Molecular Genetics and Metabolism, 106(1), 1–6.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Elisa M. Castells Martínez
    • 1
    Email author
  • Ernesto Carlos González
    • 2
  • Yileidis Tejeda
    • 3
  • Amarilys Frómeta
    • 1
  • Odalys Martín
    • 1
  • Maryeris Espinosa
    • 1
  • Lesley del Río
    • 1
  • Pedro L. Pérez
    • 1
  • Greilys Morejón
    • 4
  • Yenitse Perea
    • 1
  • Antonio Melchor
    • 5
  1. 1.Department of Neonatal ScreeningCenter of ImmunoassayHavanaCuba
  2. 2.R&D LaboratoryGK Pharmaceuticals CMOGuayamaPuerto Rico
  3. 3.ETAC UniversityTlalnepantlaMexico
  4. 4.Department of Monoclonal AntibodiesCenter of ImmunoassayHavanaCuba
  5. 5.Center of ImmunoassayHavanaCuba

Personalised recommendations